BRAF and colorectal cancer: This is a phase II trial exploring the efficacy and safety of the combination therapy rechallenge of encorafenib plus binimetinib plus cetuximab in patients with BRAF V600E-mutant unresectable advanced or recurrent colorectal cancer who have previously been treated with combination therapy including encorafenib and cetuximab.